+91-8668442535

Pulmonary Drug Delivery Devices Market By Technology (Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers), By Application (Asthma, Copd, Cystic Fibrosis, Diabetes) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

The report titled "Pulmonary Drug Delivery Devices Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall pulmonary drug delivery devices market, along with the market size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on the type of technology, application, and different geographies. Pulmonary drug delivery devices have been used for decades to deliver drugs for the treatment of respiratory diseases.

The pulmonary drug delivery pathway is considered the most efficient mode of drug delivery in respiratory diseases because the lungs provide a huge surface area of alveoli with a vast capillary network, which provides an excellent absorbing surface for the administration of drugs. Over the decade, rapid onset of action and higher efficiency were observed as the key driving factors for pulmonary delivery systems and also symptomatic relief in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Developments in device technology have also led to the development of more proficient delivery systems capable of providing large doses and microparticles into the lung.

For the purpose of this study, the global pulmonary drug delivery devices market is segmented on the basis of technology type into dry powder inhalers, metered dose inhalers, and nebulizers. Furthermore, dry powder inhalers are sub segmented into unit-dose devices and multi-dose devices. Metered-dose inhalers are of two types: manually actuated pressurized inhalers and breath-actuated pressurized inhalers. Nebulizers comprise jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The global pulmonary drug delivery devices market is also segmented on the basis of types of applications such as asthma, COPD, cystic fibrosis, diabetes, and others (allergic rhinitis, tuberculosis, among others). Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The geographical segmentation of the pulmonary drug delivery devices market comprised regions such as North America, Europe, Asia-Pacific, Latin America & the Middle East, and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. The market size and forecast for these segments during 2015–2025 and their CAGRs for the period 2017–2025 are provided in this report.

The pulmonary drug delivery devices market is observed as the most diversified and competitive market, comprising a large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are GlaxoSmithKline, Boehringer Ingelheim GmbH, 3M, AstraZeneca plc, Merck & Co., Inc., Novartis AG, Omron Corporation, and Sunovion Pharmaceuticals Inc., among others.

Based on the type of technology, the global pulmonary drug delivery devices market is segmented as follows:

Dry powder inhalers

  • Unit-dose inhalers
  • Multi-dose inhalers

Metered-dose inhalers

  • Manually-actuated, pressurized inhaler
  • Breath-actuated, pressurized inhaler

Nebulizers

  • Jet nebulizers
  • Ultrasonic wave nebulizers
  • Vibrating mesh nebulizers

Metered dose inhalers accounted for the largest market share in the pulmonary drug devices market in 2016 due to key drivers such as the rising prevalence of asthma and COPD around the world, high patient convenience, and the fact that the products and technology have penetrated the market and been observed as the most preferred technology by physicians over these years. During the forecast period of 2017–2025, dry powder inhalers were anticipated as the fastest-growing segment due to key driving factors such as short administration and preparation times, fewer irritant effects, control of the inhaled dose, and API protection. A few major brands available in the dry powder inhalers category are Spiriva, Atrovent, Foradil, Rotahaler, and FlowCaps, among others.

Based on the type of application, the global pulmonary drug delivery devices market is segmented as follows:

  • Asthma
  • COPD
  • Cystic fibrosis
  • Diabetes
  • Others (allergic rhinitis, tuberculosis, among others)

Asthma was identified as the most important application segment in the pulmonary drug delivery devices market in 2016 due to key driving factors such as a user-friendly designed device, the most efficient and convenient method of drug delivery in asthma, and the rising prevalence of asthma, which is fueling the overall growth of pulmonary drug delivery devices. Diabetes was observed as the fastest-growing segment due to ongoing research and development for pulmonary delivery of insulin, a few product approvals delivering insulin through the pulmonary pathway, high patient convenience due to non-invasive drug delivery, and the rising prevalence of diabetes globally.

For this study, the global market for pulmonary drug delivery devices is divided into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

In the base year 2016, North America accounted for the largest market share due to key driving factors such as the rising prevalence of asthma and COPD, high public awareness related to early diagnosis and treatment for respiratory disorders, developed healthcare infrastructure, and high accessibility to products with advanced technology. According to the Centers for Disease Control and Prevention (CDC), in 2015, 18.4 million adults had asthma, of which 6.2 million were children. During the forecast period of 2017–2025, Asia Pacific was observed as the fastest-growing region due to key drivers such as the rising prevalence of asthma and COPD, increasing air pollution due to rapid industrial growth, and high public awareness related to respiratory disease diagnosis. According to a report published by the United Nations (UN), globally, around seven million people a year die prematurely due to indoor and outdoor pollution, with about 70 percent of those deaths occurring in the Asia Pacific.

Frequently Asked Questions:

The market for Pulmonary Drug Delivery Devices Market is expected to reach USD 218.6 Bn By 2025.

The Pulmonary Drug Delivery Devices Market is expected to see significant CAGR growth over the coming years, at 5.4%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

GlaxoSmithKline, Boehringer Ingelheim GmbH, 3M, AstraZeneca plc, Merck & Co., Inc., Novartis AG, Omron Corporation, and Sunovion Pharmaceuticals Inc are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jul 2017
Category:  Medical Devices
Report ID:   58581
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support